Board summary
Key figures
91,722
Registered population
59.5% aged 18–64
21.1%
Aged 65+
ICB 14.9% · England 17.9%
15.5%
Ethnic minority (non-White)
10.4% Asian · England 9.6%
29.8%
In IMD quintile 1
ICB 40.7% · England 21.0%
~26,532
Core20 residents (est.)
Resident basis; registered basis ~28,561 · see page 3
15,381
Hypertension register
+5.96% in 3 yrs · England +5.60%
1,118
SMI register
44.7% of Bury (LAD)'s
2,101
COPD register
Reviews -0.64% in 3 yrs
Forecast to 2030
17,459
Hypertension patients, 2030
+2,078 on today
70.9%
QRISK ≥20% on statins, 2030
+3.60pp over 3 yrs
5.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Smoking support and diabetes control lag England.
Smoking support fell 15.6 pp to 81.4% (England 94.2%, +0.1 pp) and non-frail diabetes HbA1c control is 53.0% (England 57.4%), which may reflect recall.
Unreviewed asthma scale and youth prescribing gap.
An estimated 2,153 asthma patients lack an annual review, while 5-19 prescribing is 2,311 per 1,000 (England 1,488) and 6-19 second-hand smoke recording is.
Breast screening coverage exceeds local and national rates.
Breast screening coverage for ages 53 to 70 is 75.9% after a +7.4% 3-year change (2023 to 2024), above Bury (73.8%) and England (69.9%).
Population, age and ethnicity
A 21.1% older population and 39 care homes may elevate primary care demand
Horizon PCN has an older registered population across 91,722 patients: 21.1% (19,385) are aged 65+, above Bury (LAD) (17.6%), NHS Greater Manchester ICB (14.9%) and England (17.9%). The 0-17 cohort is 19.4% and aged 18-64 is 59.5%. Projected list growth to 2030 is 0.7% (Bury (LAD) 0.7%, ICB 1.6%, England 2.3%), with unverified methodology. Based on Census usual residents rather than GP lists, 84.5% are White and 10.4% Asian or Asian British (Bury (LAD) 10.6%, ICB 13.6%, England 9.6%), reaching 20.3% at Ribblesdale Medical Practice and 19.4% at Peel Gps.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bury (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bury LA) | 2,139 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bury LA) | 1,051 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bury LA) | 21.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 registered share is 29.8% and spans 56.6 percentage points across practices
Average IMD decile is 5.2 (Bury (LAD) 5.2 decile, NHS Greater Manchester Integrated Care Board 4.5 decile, England 5.5 decile). Core20 registered share is 29.8% (Bury (LAD) 27.9%, NHS Greater Manchester Integrated Care Board 40.7%, England 21.0%). Weighted practice share is 31.1% (a 1.34 percentage point reconciliation difference). Concentration spans 56.6 pp: Peel Gps has 59.17% (5,723 estimated patients) and Ribblesdale Medical Practice 50.77% (3,687), while Tower Family Healthcare holds 13,241 estimated patients (27.67% share). Delivery must balance intensive outreach in high-concentration practices with high-volume recall at larger lists.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,118
SMI register
1.21% recorded prevalence
533
Learning disability register
0.58% recorded prevalence
39
Care homes, 1,163 beds
In the PCN catchment
9.4%
Provide unpaid care
Bury (LAD), Census 2021
The PCN records 1,118 patients on its severe mental illness register (1.2%, above England's 1.0%) and 533 on its learning disability register (0.6%, matching England). The catchment includes 39 care homes with 1,163 beds, though beds do not confirm GP occupancy. Higher severe mental illness prevalence may indicate elevated physical-health monitoring demand, which practice-level check audits could test.
Severe mental illness: physical health checks
SMI prevalence is 1.2% (1,118 patients). Annual checks cover 76.3% for blood pressure and 76.3% for BMI, both trailing England (83.4% and 82.1%). Smoking cessation support fell 15.6 pp over 2023 to 2025 to 81.4% (England +0.1 pp, 94.2%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
15,381
Hypertension register
+5.96%
Register growth, 3 yrs
Bury (LAD) +6.10% · England +5.60%
+0.44pp
BP control, under 80
≤140/90 · +2.60pp aged 80+
+2,078
More patients by 2030
Forecast 17,459 (18.66%)
Hypertension case-finding and control
Hypertension prevalence is 16.6% (15,381 patients), above Bury (LAD) (15.2%), NHS Greater Manchester Integrated Care Board (14.4%), and England (15.2%). For patients aged under 80 with hypertension, blood pressure control within the last 12 months is 67.3%, trailing Bury (LAD) (67.7%), NHS Greater Manchester Integrated Care Board (68.6%), and England (67.8%). Three-year growth (+0.7%, 2023 to 2025) lagged Bury (LAD) (+6.4%) and England (+3.2%). Observation periods for prevalence are not supplied. Lower blood pressure control among younger hypertensive patients may indicate a need to audit recall and titration routines against benchmark performance.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid-lowering therapy stand at 63.0%, trailing Bury (LAD) (64.2%), NHS Greater Manchester Integrated Care Board (67.0%), and England (63.6%). Patients aged 40+ with diabetes and no CVD history treated with a statin reach 71.0% (England 73.2%). Gaps may reflect review patterns, which audit could test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 174,417 | £1.90 | £1.94 | £1.86 | £331,392 |
| Cardiovascular (all), 2025 | 233,849 | £3.42 | £3.15 | £3.33 | £799,764 |
Prescribing for lipid-regulating drugs in 2026 totaled 174,417 items at £1.90 per item (£331,392 spend), compared to £1.91 in Bury (LAD), £1.94 in NHS Greater Manchester Integrated Care Board, and £1.86 in England. The PCN spends £6,977 more than at England's unit cost, across 174,417 items. Unit cost differences do not establish efficiency or formulary choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+38.57%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.68%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.3% (6,384 patients; England 6.6%). Annual reviews rose +38.6% over 2023 to 2025 (England +4.4%) to 66.3% (England 65.7%), leaving an estimated 2,153 register patients unreviewed. Prescribing for ages 5 to 19 is 2,311 items per 1,000 (England 1,488), while second-hand smoke recording for ages 6 to 19 is 69.1% (England 78.8%). COPD prevalence is 2.3% (2,101 patients; England 1.9%), but the register fell 3.0% over 2023 to 2025 (England +2.6%). High youth prescribing may reflect exposure risks, which review audits could test.
Cancer register and children's immunisation
Cancer prevalence is 4.7% (4,345 patients; England 3.8%). In Q1 2025/26 supplementary data, MMR dose 1 coverage at 24 months was 85.0% (England 88.3%). By age five, MMR dose 1 reached 95.7% (England 91.7%), but dose 2 dropped 9.1 pp to 86.6% (England 82.8%). The gap between first and second dose at age five may reflect timing of pre-school recalls, which practice-level call audits could clarify.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In NHS Greater Manchester ICB, 55.6% of cancers were diagnosed at stage 1 or 2 in 2022 (England 55.3%), sitting 19.4 pp below the 75.0% national ambition by 2028. Reaching that ambition would require about 2,270 extra early-stage cases annually across the ICB. While Horizon PCN records 68.1% cervical screening coverage (England 66.8%), practice coverage varies, dropping to 55.3% at Peel Gps and 59.2% at Ribblesdale Medical Practice. Early-stage diagnosis data was not captured at PCN level and does not measure PCN performance. Lower practice-level screening coverage may delay early detection for registered cohorts, which recall audits could test.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For July 2026 (provisional), Bolton NHS Foundation Trust achieved 69.7% on the cancer 62-day referral to treatment standard, trailing England (71.2%) and remaining 15.3 pp below the 85.0% standard. NHS Greater Manchester ICB reached 75.7% (9.3 pp below the standard). Conversely, Bolton NHS Foundation Trust met the 28-day faster diagnosis standard at 80.5%, exceeding the 75.0% standard (ICB 79.5%, England 79.3%). These operational waiting times reflect acute trust performance and do not establish PCN-level patient delays. System-level treatment delays highlight the need for robust safety-netting following urgent referrals.
| Pathways within standard (%) | Bolton | Northern Care Alliance | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 75.20 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 94.54 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 78.65 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Northern Care Alliance | Manchester | England |
|---|---|---|---|---|
| MRI | 2.05 | 5.09 | 11.68 | 21.40 |
| CT | 19.40 | 4.10 | 14.66 | 9.92 |
| Echocardiography | 3.48 | 31.48 | 4.91 | 28.48 |
| Colonoscopy | 1.33 | 40.04 | 4.51 | 30.83 |
| Gastroscopy | 2.06 | 36.48 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.78 | 15.71 | 8.98 | 23.14 |
| Community services activity | Bury residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 58,875 | 573,310 |
| Referrals | 7,435 | 94,470 |
| Patients with a contact | 16,745 | 183,535 |
Community services (residents of Bury), Jun 2026 (provisional). In June 2026 (provisional), community contacts with adults aged 65+ accounted for 43.7% of all contacts for Bury borough residents (25,735 of 58,875). These figures capture borough-wide resident activity and do not represent PCN-specific service delivery. Heavy borough community contact volumes among older adults indicate substantial local intermediate-care reliance.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF clinical-domain achievement was 98.4% at Woodbank Surgery and 100.0% at Garden City Medical Centre, compared to 97.1% for England. The range across captured practices in QOF vaccination and immunisation-domain achievement was 60.3 pp. Woodbank Surgery achieved 15.6%, whereas Garden City Medical Centre achieved 76.0% (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Garden City | 102 | 2.5 | 76.4% | 71.7% | 91.8% |
| Peel Gps | 97 | 59.2 | 59.6% | 66.4% | 80.2% |
| Mile Lane | 103 | 12.2 | 48.8% | 63.7% | 73.2% |
| Ribblesdale | 99 | 50.8 | 60.5% | 65.4% | 70.2% |
| Tower Family | 118 | 27.7 | 48.1% | 71.1% | 66.9% |
| Red Bank | 100 | 38.6 | 28.0% | 58.5% | 66.6% |
| Woodbank Surgery | 90 | 23.7 | 44.4% | 79.7% | 60.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 tracked measures trailed England trends between 2023 and 2025
Over 2023 to 2025, 16 of 25 tracked measures trailed England. Smoking cessation support fell 15.6 pp to 81.4% (England +0.1 pp, 94.2%), trailing England by 15.67 pp. Non-frail diabetes HbA1c control fell 1.6% to 53.0% (England +4.4%, 57.4%), while heart failure reviews rose +2.4% (England +8.7%). In contrast, asthma reviews increased +38.6% (England +4.4%). Severe mental illness checks also improved: BMI recording rose +11.3 pp to 76.3% (England +5.1 pp, 82.1%) and alcohol recording rose +11.4 pp (England +5.4 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Smoking support (SMI)
Heart failure reviews
Diabetes HbA1c control
COPD register
Learning disability register
Asthma reviews
BMI record (SMI)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bury (LAD) | Asset | PCN | Bury (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 39 (1,163 beds) | n/a | Schools (catchment) | 120 | n/a |
| Children's centres | 5 | 8 | Places of worship | 75 | 107 |
| Libraries | 8 | 12 | Primary schools (LA maintained) | 22 | 25 |
| Primary academies | 24 | 33 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and youth smoke reviews
Asthma reviews reached 66.3% (England 65.7%), leaving an estimated 2,153 of 6,384 patients unreviewed; 5-19 prescribing is 2,311 per 1,000 (England 1,488) and 6-19 smoke recording is 69.1% (England 78.8%). For discussion: practices could run a single-template recall for unreviewed asthma patients, pairing inhaler prescribing checks with second-hand smoke recording. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Cardiometabolic, SMI and smoking recall
Non-frail diabetes HbA1c control is 53.0% (2,740 of 5,171 in 2024/25; England 57.4%; 3-year change -1.6% vs England +4.4%), SMI BP checks are 76.3% (England 83.4%), and smoking support fell 15.6 pp to 81.4% (England +0.1 pp, 94.2%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Learning disability register validation
Learning disability prevalence is 0.6% (533 of 91,722 patients); 3-year growth (+1.4%, 2023 to 2025) trailed Bury (LAD) (+3.6%) and England (+5.4%), giving a modelled range of +6 to +13 patients. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult anticipatory care coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Mental health physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma and youth smoke reviews (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Cardiometabolic, SMI and smoking recall (p12) | Diabetes without frailty: HbA1c at or below 58 mmol/mol · IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs) · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
